ABSTRACT
Myall et al provide a response to the comment of Denneny et al on their paper regarding the role for steroids in COVID-19-associated pneumonitis at six-week follow-up. Given the risk factors for severe COVID-19 pneumonitis, they agree that steroid therapy is not without risk in this group. Individual patient discussion was key, and hence, five patients did not commence steroid treatment after review. It is therefore worth noting that the quoted proportions of patients with comorbidity refers to the whole cohort referred to the interstitial lung disease (ILD) service and not to the treatment group, who had lower rates of comorbidity. All patients had weekly telephone support and diabetes team input as appropriate. As a result, they saw no major complications of treatment.